Neonc Technologies Holdings, Inc. · NASDAQ:NTHI
Neonc Technologies — Technical Presentation (November 2025)
21 slides from Neonc Technologies's technical presentation, Nov 12, 2025
Slide 1: Significant Radiographic Response and Long-Term Survival in Recurrent WHO Grade 3/4 Astrocytoma Treated with Intranasal NEO100
Significant Radiographic Response and Long - Term Survival in Recurrent WHO Grade 3/4 IDH1 - mutant Astrocytoma Treated with Intranasal NEO100 Amir Heshmatpour , Executive Chairman, President & CEO Dr. Thomas C Chen, Chief Medical Officer Dr. Josh Neman, Chief Clinical Officer Dr. Henry Friedman, Ch
Slide 2: Meeting Agenda
Meeting Agenda • Introductions – Amir Heshmatpour • Purpose of Meeting – Dr. Thomas Chen • NEO100 - 1 Phase 2a update – Dr. Josh Neman • NEO100 Radiographic Response - Dr. Thomas Chen • Long Term Survivors – Dr. Josh Neman and Dr. Thomas Chen • Discussion – Drs. Henry Friedman, Alex Miller • Q&A and
Slide 3: Phase 2 Development & Clinical Pipeline
Phase 2 Development & Clinical Pipeline 3 FDA Authorized Clinical Trials Commercialization Phase III Phase II Phase I IND Enabling * Preclinical Indication Application Drug Candidate Recurrent Grade III & Grade IV Astrocytoma Brain Cancer w/ IDH1 Mutation Intranasal NEO100 - 01 Meningioma Brain Tumo
Slide 4: NEO100 - Phase 2a Objectives
NEO100 - 1 Phase 2a Objectives Eligibility Requirements: • Patients with WHO recurrent isocitrate dehydrogenase - 1 (IDH1) – mutant Grade 3/4 Astrocytoma Primary Objective ● Determine Progression - Free Survival at 6 months (PFS - 6). Secondary Objectives ● Assess Objective Response Rate (ORR) by RA
Slide 5: NEO100 - Phase 2a: 6-Month Progression Free Survival
NEO100 - 01 Phase 2a: 6 - Month Progression Free Survival Historical IDH1 mut recurrent HGG 1,2 NEO100 - 01 Metric 21 - 31% 44% (8/18) 6 months Progression Free Survival References: 1 Fanucci et al., 2023 2 Walbert et al. 2010 ≥6 - month follow - up prior to data cutoff.
Slide 6: Significant Radiographic Response and Long Term Survivor Cohort Summary
Significant Radiographic Response and Long Term Survivor Cohort Summary Patients with recurrent isocitrate dehydrogenase - 1 (IDH1) – mutant WHO Grade 3/4 Astrocytoma A total of 24 patients received intranasal NEO100 across Phase 1 (n=5) and Phase 2a (n=18) clinical trials, as well as one compassion
Slide 7: NEO100 - Radiographic Response and Long Term Survival
NEO100 - 1 Radiographic Response Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO Diagnosis Age as of 10/4/2025 Sex Study Phase Patient ID Y, 8.38 4.83 Y 58 6/4/18 6/16/2017 Both Astrocytoma, I
Slide 8: Patient case history: WHO Grade IV Astrocytoma, MGMT-unmethylated
• Diagnosis: WHO Grade IV IDH1 - mutant Astrocytoma , MGMT - unmethylated • Presentation: Seizure on 01 Feb 2022 → MRI showed new partially necrotic left parietal mass (5.7 î 3.4 î 4.6 cm) with nodular enhancement and intratumoral hemorrhage involving the splenium of the corpus callosum with mild co
Slide 9: Patient MRI tumor measurements across cycles
Cycle 8 1.1 AP x 1.5 TR cm Cycle 34 .31 AP x .71 TR cm Baseline (Pre - NEO100) ~ 4.7cm Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO Diagnosis Age as of 10/4/2025 Sex Study Phase Patient ID
Slide 10: Patient case history: WHO Grade IV Astrocytoma
• Diagnosis: WHO Grade IV IDH1 - mutant Astrocytoma, MGMT status unknown • Initial Management: Surgical resection on 16 Jun 2017 • Adjuvant Therapy: – Radiation therapy: 24 Aug 2017 – 05 Oct 2017 – Temozolomide (4 cycles): 24 Nov 2017 – 22 Apr 2018 – Optune device: Used concurrently with temozolomid
Slide 11: Patient MRI tumor measurements across cycles
Baseline (Pre - NEO100) 0.63 AP x 1.39 TR cm Cycle 2 0.64 AP x 1.55 TR cm Cycle 57 0 AP x 0 TR cm Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO diagnosis Age as of 10/4/2025 Sex Study Phase
Slide 12: Patient case history: WHO Grade IV Astrocytoma
• Diagnosis: WHO Grade IV IDH1 - mutant Astrocytoma, MGMT status unknown • Initial Management: Biopsy on 18 May 2023, followed by resection on 27 Jun 2023 • Adjuvant Therapy: – Radiation therapy: 31 Jul 2023 – 20 Sep 2023 – Temozolomide (1 cycle): 31 Jul 2023 – 07 Aug 2023 • Subsequent Therapy (afte
Slide 13: Patient MRI tumor measurements across cycles
Baseline (Pre - NEO100) . 49 AP x .60 TR cm Cycle 2 .52 AP x .52 TR cm Cycle 12 0 AP x 0 TR Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO diagnosis Age as of 10/4/2025 Sex Study Phase Patien
Slide 14: Patient case history: WHO Grade IV Astrocytoma
• Diagnosis: WHO Grade IV IDH1 - mutant Astrocytoma , MGMT status unknown • Initial Management: Surgical resection on 12 Oct 2018 → pathologic diagnosis confirmed 18 Oct 2018 • Adjuvant Therapy: Radiation therapy + Temozolomide , 13 Feb 2019 – 16 May 2019 • Screening MRI: 06 Mar 2025 • Clinical Tria
Slide 15: Patient MRI tumor measurements across cycles
Baseline (Pre - NEO100) 1.42 AP x 1.37 TR cm Cycle 2 1.00 AP x 1.23 TR cm Cycle 7 1.67 AP x 1.37 TR cm Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO diagnosis Age as of 10/4/2025 Sex Study P
Slide 16: Patient case history: WHO Grade IV Astrocytoma, MGMT-unmethylated
• Diagnosis: WHO Grade IV IDH1 - mutant Astrocytoma , MGMT - unmethylated , • Initial Management: Underwent surgical resection on 08 May 2024 • Adjuvant Therapy: • Radiation therapy: 24 Jun 2024 – 05 Aug 2024 • Temozolomide: 02 Sep 2024 – 13 Jan 2025 • Screening MRI: 31 Mar 2025 • Clinical Trial Enr
Slide 17: Patient MRI tumor measurements across cycles
Baseline (Pre - NEO100) . 73 AP x .35 TR cm Cycle 2 .58 AP x .36 TR cm Cycle 6 .58 AP x .75 TR cm Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO Diagnosis Age as of 10/4/2025 Sex Study Phase
Slide 18: Long-Term Survival: Recurrent WHO Grade 3/4 Astrocytoma
Long - Term Survival: Recurrent WHO Grade 3/4 IDH1 - mutant Astrocytoma • No major toxicity reported across cohort; chronic intranasal dosing well tolerated • Adverse events predominantly low - grade; safety consistent with prolonged exposure + Subject alive 8 of 24 patients are long - term survivor
Slide 19: Summary: NEO100 Clinical Outcomes for Recurrent WHO Grade 3/4 Astrocytoma
Summary: NEO100 - 01 Clinical Outcomes for Recurrent WHO Grade 3/4 IDH1 - mutant Astrocytoma Progression - Free Survival: 44% of patients achieved 6 - month progression - free survival (PFS - 6), outperforming historical benchmarks of 21 – 31% for IDH1 - mutant recurrent high - grade gliomas. Radiog
Slide 20: Impact & Significance
Impact & Significance • First - of - its - kind signal for durable response: MRI - confirmed significant response in setting rarely seen • Potential paradigm shift with multi - year survival: CNS - penetrant metabolic therapy • Differentiation: Minimal toxicity vs. standard salvage therapies • Trans
Slide 21: Discussion and Q&A
Significant Radiographic Response and Long - Term Survival in Recurrent WHO Grade 3/4 IDH1 - mutant Astrocytoma Treated with Intranasal NEO100 Discussion – Drs. Henry Friedman, Alex Miller Q&A NEO100 is a patented Investigational New Drug (IND) patented to NeOnc Technologies Holdings Inc. (Nasdaq: N
NeOnc Technologies Holdings — Technical Presentation (November 2025) on 6ix